A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
Applied Health Economics and Health Policy · 2024
DOI: 10.1007/s40258-023-00867-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Health Economics and Health Policy, 2024. Verfasst von Néboa Zozaya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics, Weber, C/Moreto 17, 5D, 28014, Madrid, Spain. neboa.zozaya@weber.org.es. Hauptthemen laut MEDLINE: Organisation for Economic Co-Operation and Development, Technology Assessment, Biomedical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 154 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: The aim of this study was to review the current evaluation and funding processes for new drugs in different developed countries, to provide a comparative framework with detailed, homogeneous, and up-to-date information. METHODS: Scientific publications, reports and websites were reviewed between July and December 2021 using PubMed, Google Scholar, and grey literature sources. The main items searched were actors and processes, including timelines, characteristics of clinical and economic evaluations, participation of stakeholders, elements of price and reimbursement decisions, cost-effectiveness thresholds and specific funds. The analysed 13 countries were Australia, Canada, England, France, Germany, Italy, Japan, the Netherlands, Portugal, Scotland, South Korea, Spain and Sweden. RESULTS: Eight countries perform the assessment process separated from the pricing decision. Countries measure each drug's added therapeutic value through multi-attribute value scales, algorithms, non-prescriptive lists of criteria, or quality-adjusted life years (QALYs). Health technology assessment (HTA) methodologies differ in their outcome measures, elicitation techniques, comparators, and perspectives. The criteria used for pricing and reimbursement include humanistic, clinical, and economic aspects. Only Scotland, England, the Netherlands, Canada and Portugal use explicit efficiency thresholds. Health care professionals participate in all assessment committees, and patients are becoming increasingly involved in most countries. The official time from marketing authorisation to the completion of the evaluation and pricing processes varied from 126 to 540 days. CONCLUSIONS: Most analysed countries show a trend towards value-based approaches that consider value for money to society, but also other economic, clinical, and humanistic criteria. Good practices included robustness, transparency, independence, and participation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Health Economics, Weber, C/Moreto 17, 5D, 28014, Madrid, Spain. neboa.zozaya@weber.org.es.
- Department of Quantitative Methods in Economics and Management, Faculty of Economics, Business and Tourism, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. neboa.zozaya@weber.org.es.
- Department of Health Economics, Weber, C/Moreto 17, 5D, 28014, Madrid, Spain.
- King Juan Carlos University & Syracuse University, Madrid, Spain.
- Department of Pharmacy, Hospital Universitario Virgen Macarena, Seville, Spain.
- Ministry of Health, Madrid, Spain.
ORCID-Profile: Néboa Zozaya, Javier Villaseca, Fernando Abdalla, Miguel Ángel Calleja, Jorge Mestre-Ferrándiz, Juan Oliva-Moreno, José Luis Trillo, Álvaro Hidalgo-Vega
Zitieren
APA
Zozaya, N., Villaseca, J., Fernández, I., Abdalla, F., Cadenas-Noreña, B., Calleja, M. Á., Gómez-Pajuelo, P., Mestre-Ferrándiz, J., Oliva-Moreno, J., Trillo, J. L., & Hidalgo-Vega, Á. (2024). A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-023-00867-9
Vancouver
Zozaya N, Villaseca J, Fernández I, Abdalla F, Cadenas-Noreña B, Calleja MÁ, et al. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied Health Economics and Health Policy. 2024. doi:10.1007/s40258-023-00867-9
BibTeX
@article{Zozaya2024,
author = {Zozaya, Néboa and Villaseca, Javier and Fernández, Irene and Abdalla, Fernando and Cadenas-Noreña, Benito and Calleja, Miguel Ángel and Gómez-Pajuelo, Pedro and Mestre-Ferrándiz, Jorge and Oliva-Moreno, Juan and Trillo, José Luis and Hidalgo-Vega, Álvaro},
title = {A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries},
journal = {Applied Health Economics and Health Policy},
year = {2024},
doi = {10.1007/s40258-023-00867-9}
}
EUVIMED